All AbMole products are for research use only, cannot be used for human consumption.
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent, potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle blocking, apoptosis, or autophagy in acute myeloid leukemia.
| Molecular Weight | 495.43 |
| Formula | C25H17F4N5O2 |
| CAS Number | 1616428-23-9 |
| Solubility (25°C) | DMSO ≥ 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related FLT3 Products |
|---|
| 4SC-203
4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. |
| AKN-028
AKN-028, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6 nM. |
| FLT3-IN-3
FLT3-IN-3 is a potent FLT3 inhibitor with IC50s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively. |
| MAX-40279
MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. |
| FLT3-IN-10
FLT3-IN-10 is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
